Owners, management and financials
CVR: 32323537
Previous names: ACP 30.06.2012 2 A/S, ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S
EUR 140,817,000
Revenue
Net result: EUR -38,806,000
ASCENDIS PHARMA A/S (100%)
CVR · view owners
Jan Møller Mikkelsen
Board: Michael Wolff Jensen (chair) and 2 members
CVR · view management
Active
Founded 29 June 2012
CVR · view overview
0 employees
Annual report 2025 · average
Name registered: Ascendis Pharma Endocrinology Division A/S
CVR · 14/03/2016
View the full event history
Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.
Source: annual report 2025, Danish Business Authority
The financial health of Ascendis Pharma Endocrinology Division A/S appears concerning, with a significant decline in profitability and a negative equity position that has worsened over the years. In 2025, the company reported revenue of €140.8 million and a gross profit of €67.2 million, but still incurred a loss of €38.8 million, reflecting ongoing challenges in achieving profitability. Notably, equity has plummeted from -€509.2 million in 2021 to -€935.7 million in 2025, indicating increasing financial strain. The company's negative gross profit in previous years highlights persistent operational difficulties, raising concerns about its sustainability and competitive position within the pharmaceutical manufacturing industry.
AI-generated summary · Generated 20/08/2026
Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 140.8 mio. EUR | -38.8 mio. EUR | 78.1 mio. EUR | -935.6 mio. EUR | 0 | |
| 202401/01/2024 – 31/12/2024 | 122.9 mio. EUR | -121.1 mio. EUR | 25.3 mio. EUR | -896.8 mio. EUR | 0 | |
| 202301/01/2023 – 31/12/2023 | - | -60.9 mio. EUR | 102.2 mio. EUR | -775.7 mio. EUR | 0 | |
| 202201/01/2022 – 31/12/2022 | - | -205.6 mio. EUR | 55.4 mio. EUR | -714.8 mio. EUR | 0 | |
| 202101/01/2021 – 31/12/2021 | - | -98.9 mio. EUR | 43.2 mio. EUR | -509.2 mio. EUR | 0 | |
| 202001/01/2020 – 31/12/2020 | - | -107.5 mio. EUR | 44 mio. EUR | -410.3 mio. EUR | 0 | |
| 201901/01/2019 – 31/12/2019 | - | -95 mio. EUR | 27.8 mio. EUR | -302.8 mio. EUR | 0 | |
| 201801/01/2018 – 31/12/2018 | - | -59.2 mio. EUR | 34.6 mio. EUR | -207.7 mio. EUR | 0 | |
| 201701/01/2017 – 31/12/2017 | - | -60.3 mio. EUR | 12.5 mio. EUR | -148.6 mio. EUR | 0 | |
| 201601/01/2016 – 31/12/2016 | - | -44 mio. EUR | 3.7 mio. EUR | -88.3 mio. EUR | - | |
| 201501/01/2015 – 31/12/2015 | - | -29.6 mio. EUR | 5.4 mio. EUR | -44.3 mio. EUR | - | |
| 201401/01/2014 – 31/12/2014 | - | -11.5 mio. EUR | 1 mio. EUR | -14.7 mio. EUR | - | |
| 201301/01/2013 – 31/12/2013 | - | -47.3 mio. | 27.7 mio. | -36.9 mio. | - |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Ascendis Pharma Endocrinology Division A/S is 32323537.
Ascendis Pharma Endocrinology Division A/S is owned by ASCENDIS PHARMA A/S.
The management of Ascendis Pharma Endocrinology Division A/S consists of Jan Møller Mikkelsen.
The board of Ascendis Pharma Endocrinology Division A/S consists of Michael Wolff Jensen, Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen, with Michael Wolff Jensen as chair.
In 2025, Ascendis Pharma Endocrinology Division A/S reported revenue of EUR 140,817,000.
Ascendis Pharma Endocrinology Division A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2025. Revenue came to DKK 140,817,000, and the net result was DKK -38,806,000.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2024. Revenue came to DKK 122,880,000, and the net result was DKK -121,118,000.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2023. Gross profit came to DKK -36,071,762, and the net result was DKK -60,902,993.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2022. Gross profit came to DKK -189,944,253, and the net result was DKK -205,626,348.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2021. Gross profit came to DKK -86,451,578, and the net result was DKK -98,887,391.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2020. Gross profit came to DKK -98,477,366, and the net result was DKK -107,518,319.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2019. Gross profit came to DKK -89,300,964, and the net result was DKK -95,044,994.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2018. Gross profit came to DKK -54,429,523, and the net result was DKK -59,159,586.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2017. Gross profit came to DKK -57,341,190, and the net result was DKK -60,324,124.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2016. Gross profit came to DKK -42,307,040, and the net result was DKK -44,006,494.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2015. Gross profit came to DKK -28,800,471, and the net result was DKK -29,557,717.
On March 14, 2016, the company changed its name from ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S to Ascendis Pharma Endocrinology Division A/S.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2014. Gross profit came to DKK -11,220,985, and the net result was DKK -11,532,115.
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2013. Gross profit came to DKK -46,231,581, and the net result was DKK -47,307,843.
Ascendis Pharma Endocrinology Division A/S has published its interim report for the period June 29, 2012 – December 31, 2012.
On January 30, 2013, the company changed its name from ACP 30.06.2012 2 A/S to ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S.
As of June 29, 2012, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Ascendis Pharma Endocrinology Division A/S.
As of June 29, 2012, Michael Wolff Jensen has joined the board of directors of Ascendis Pharma Endocrinology Division A/S.
As of June 29, 2012, Jan Møller Mikkelsen has joined the board of directors of Ascendis Pharma Endocrinology Division A/S.
As of June 29, 2012, Anni Lotte Kirstine Pedersen has joined the board of directors of Ascendis Pharma Endocrinology Division A/S.
As of June 29, 2012, Jan Møller Mikkelsen is registered as adm. dir. of Ascendis Pharma Endocrinology Division A/S.
As of June 29, 2012, ASCENDIS PHARMA A/S is registered as an owner of Ascendis Pharma Endocrinology Division A/S with an ownership share of 100%.
Ascendis Pharma Endocrinology Division A/S was founded on June 29, 2012.
Companies in the same industry and area
CVR 29918791
CVR 32323502
CVR 37011185
CVR 46029518
CVR 41101970
